BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 27, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Eisbach receives investment for first-in-human study of EIS-12656 for refractory solid tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Eisbach receives investment for first-in-human study of EIS-12656 for refractory solid tumors
March 22, 2024
No Comments
Cancer Focus Fund LP, an investment fund established in collaboration with The University of Texas MD Anderson Cancer Center, is investing $4.5 million to support a first-in-human trial of Eisbach Bio GmbH’s lead candidate, EIS-12656.
BioWorld Science
Financings
Cancer